GENFIT-ADR (GNFT) Stock Fundamental Analysis
NASDAQ:GNFT - Nasdaq - US3722791098 - ADR - Currency: USD
Taking everything into account, GNFT scores 4 out of 10 in our fundamental rating. GNFT was compared to 550 industry peers in the Biotechnology industry. While GNFT is still in line with the averages on profitability rating, there are concerns on its financial health. GNFT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
GNFT had positive earnings in the past year.
GNFT had a positive operating cash flow in the past year.
In multiple years GNFT reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of GNFT (1.00%) is better than 90.55% of its industry peers.
With an excellent Return On Equity value of 2.18%, GNFT belongs to the best of the industry, outperforming 91.64% of the companies in the same industry.
The Return On Invested Capital of GNFT (3.45%) is better than 92.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROIC | 3.45% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GNFT has a better Profit Margin (2.12%) than 91.09% of its industry peers.
GNFT's Profit Margin has declined in the last couple of years.
GNFT has a better Operating Margin (4.55%) than 92.55% of its industry peers.
In the last couple of years the Operating Margin of GNFT has declined.
Looking at the Gross Margin, with a value of 97.11%, GNFT belongs to the top of the industry, outperforming 97.45% of the companies in the same industry.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
GNFT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GNFT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GNFT has been increased compared to 5 years ago.
GNFT has a worse debt/assets ratio than last year.
2.2 Solvency
GNFT has an Altman-Z score of -1.76. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a Altman-Z score of -1.76. This is comparable to the rest of the industry: GNFT outperforms 56.55% of its industry peers.
The Debt to FCF ratio of GNFT is 4.26, which is a neutral value as it means it would take GNFT, 4.26 years of fcf income to pay off all of its debts.
GNFT's Debt to FCF ratio of 4.26 is amongst the best of the industry. GNFT outperforms 93.45% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that GNFT is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.08, GNFT is not doing good in the industry: 63.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | -1.76 |
ROIC/WACC0.48
WACC7.16%
2.3 Liquidity
A Current Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
The Current ratio of GNFT (1.23) is worse than 85.27% of its industry peers.
GNFT has a Quick Ratio of 1.23. This is a normal value and indicates that GNFT is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.23, GNFT is not doing good in the industry: 84.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
GNFT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.17%, which is quite impressive.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
Looking at the last year, GNFT shows a very strong growth in Revenue. The Revenue has grown by 85.82%.
GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
3.2 Future
The Earnings Per Share is expected to decrease by -45.31% on average over the next years. This is quite bad
The Revenue is expected to decrease by -1.99% on average over the next years.
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.49%
Revenue Next 2Y-22.29%
Revenue Next 3Y-5.23%
Revenue Next 5Y-1.99%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 94.75, which means the current valuation is very expensive for GNFT.
Based on the Price/Earnings ratio, GNFT is valued cheaper than 90.36% of the companies in the same industry.
GNFT is valuated expensively when we compare the Price/Earnings ratio to 26.73, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 94.75 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GNFT is valued cheaply inside the industry as 92.91% of the companies are valued more expensively.
96.73% of the companies in the same industry are more expensive than GNFT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.19 | ||
| EV/EBITDA | 28.45 |
4.3 Compensation for Growth
GNFT has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as GNFT's earnings are expected to decrease with -45.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.31%
EPS Next 3YN/A
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:GNFT (8/12/2025, 8:00:01 PM)
3.79
+0.06 (+1.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1%
Inst Owner Change0%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap189.51M
Analysts90.77
Price Target10.49 (176.78%)
Short Float %0.08%
Short Ratio9.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.86%
PT rev (3m)1.47%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-9.34%
Revenue NY rev (3m)-4.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 94.75 | ||
| Fwd PE | N/A | ||
| P/S | 2.3 | ||
| P/FCF | 11.19 | ||
| P/OCF | 10.49 | ||
| P/B | 2.36 | ||
| P/tB | 7.68 | ||
| EV/EBITDA | 28.45 |
EPS(TTM)0.04
EY1.06%
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)0.34
FCFY8.94%
OCF(TTM)0.36
OCFY9.54%
SpS1.65
BVpS1.61
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROCE | 4.23% | ||
| ROIC | 3.45% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% | ||
| FCFM | 20.54% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 1.12 | ||
| Cap/Depr | 56.79% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 314.19% | ||
| Profit Quality | 966.82% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -1.76 |
F-Score7
WACC7.16%
ROIC/WACC0.48
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
Revenue Next Year-6.49%
Revenue Next 2Y-22.29%
Revenue Next 3Y-5.23%
Revenue Next 5Y-1.99%
EBIT growth 1Y112.1%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year67.69%
EBIT Next 3Y62.39%
EBIT Next 5YN/A
FCF growth 1Y125.16%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y128.05%
OCF growth 3Y-46.21%
OCF growth 5YN/A